Generated by Rank Math SEO, this is an llms.txt file designed to help LLMs better understand and index this website.

# Thirona

## Sitemaps
[XML Sitemap](https://thirona.eu/sitemap_index.xml): Includes all crawlable and indexable pages.

## Posts
- [How AI-Based 3D Visualization Supports More Precise, Lung-Sparing Surgery for Lung Cancer Patients](https://thirona.eu/how-ai-based-3d-visualization-supports-more-precise-lung-sparing-surgery-for-lung-cancer-patients/): Featuring insights from Mirjam Davidse and Quirijn Tummers
- [Thirona and SEPAR Launch an Educational Project for Pulmonologists on AI-Based Quantitative CT Analysis in Severe Asthma](https://thirona.eu/thirona-and-separ-launch-an-educational-project-for-pulmonologists-on-ai-based-quantitative-ct-analysis-in-severe-asthma/): Thirona has partnered with the Spanish Society of Pulmonology and Thoracic Surgery (SEPAR) to launch an educational initiative designed to familiarize clinical specialists with AI-enabled quantitative CT (QCT) analysis in severe asthma. The program supports pulmonologists in understanding how advanced imaging-based analysis methods can provide deeper insights into disease presentation and variability. 
- [Structural Insights in Severe Asthma Paving the Way for More Precise Treatment Stratification  ](https://thirona.eu/structural-insights-in-severe-asthma-paving-the-way-for-more-precise-treatment-stratification/): Featuring insights from prof. Arnaud Bourdin, University of Montpellier
- [Redefining Bronchiectasis Trials Through AI-Powered Image Analysis](https://thirona.eu/redefining-bronchiectasis-trials-through-ai-powered-image-analysis/): By Prof. dr. Harm Tiddens, MD
- [Thirona Receives FDA Clearance for LungQ® 4 Software, Expanding AI-Powered Capabilities in Lung Image Analysis for the U.S. Market](https://thirona.eu/lungq4-receives-fda-510k-clearance/): Thirona Receives FDA Clearance for LungQ® 4 Software, Expanding AI-Powered Capabilities in Lung Image Analysis for the U.S. Market.
- [Thirona and VIDA Diagnostics Partner to Accelerate Respiratory Clinical Trials with Advanced AI Imaging](https://thirona.eu/thirona-and-vida-diagnostics-partner-to-accelerate-respiratory-clinical-trials-with-advanced-ai-imaging/): Thirona, global experts in AI-powered lung image analysis, and VIDA Diagnostics, the clinical imaging intelligence leader announced a strategic partnership at the European Respiratory Society (ERS) meeting in Amsterdam. This collaboration will make Thirona's advanced quantitative analyses available to a wider network of trial sponsors through VIDA's Intelligence Platform.
- [Comprehensive assessment of mucus impaction with Artificial Intelligence](https://thirona.eu/comprehensive-assessment-of-mucus-impaction-with-artificial-intelligence/): By Thirona Editorial Team
- [Artificial Intelligence detects substantial airway damage on CT scans of children with severe asthma](https://thirona.eu/artificial-intelligence-detects-substantial-airway-damage-on-ct-scans-of-children-with-severe-asthma-2/): This blog provides a brief summary of a recent study "Children with severe asthma have substantial structural airway changes on computed tomography" by Wytse B. van den Bosch et al. (ERS Journal, Jan'2024), highlighting key insights and potential impact on treatment of the disease.
- [Renewed ISO 13485 and MDR Approvals, and our 1st MDSAP Certification](https://thirona.eu/renewed-iso-13485-and-mdr-approvals-and-our-1st-mdsap-certification/): We are proud to announce that Thirona has successfully renewed its ISO 13485 and EU MDR certifications and, for the first time, achieved certification under the Medical Device Single Audit Program (MDSAP) - a major milestone in strengthening our global regulatory foundation.
- [Welcoming internationally renowned pulmonologists to Thirona’s Medical Advisory Board](https://thirona.eu/welcoming-internationally-renowned-pulmonologists-to-thironas-medical-advisory-board/): We are proud to announce the expansion of our Medical Advisory Board with the addition of three world-renowned pulmonologists
- [Thirona and COPD Foundation Partner to Advance AI-Driven Phenotyping of COPD Patients](https://thirona.eu/thirona-and-copd-foundation-partner-to-advance-ai-driven-phenotyping-of-copd-patients/): A new Thirona–COPD Foundation study will assess AI-derived QCT biomarkers in over 10,000 COPDGene participants to support advanced phenotyping and targeted treatment.
- [AI in phenotyping of pulmonary blood vessels: Redefining diagnosis and treatment of pulmonary vascular diseases](https://thirona.eu/ai-in-phenotyping-of-pulmonary-blood-vessels-redefining-diagnosis-and-treatment-of-pulmonary-vascular-diseases/): Leticia Gallardo Estrella, Lead Deep Learning Engineer at Thirona, shares the recent developments in vascular phenotyping of pulmonary disease, elaborating on the possibilities and benefits of AI-powered pulmonary vessel differentiation.
- [4 Critical Steps to Effective Clinical Trials with Lung Imaging](https://thirona.eu/4-critical-steps-to-effective-clinical-trials-with-lung-imaging/): Jean-Paul Charbonnier, CIO of Thirona explains 4 critical steps to effectively applying AI-enabled lung image analysis in pulmonary clinical trials. 
- [Beyond the Algorithm – Driving Clinical Impact Through Compliance](https://thirona.eu/beyond-the-algorithm-driving-clinical-impact-through-compliance/): Innovation only matters when it can be trusted in clinical practice. This article explores how regulatory rigor and a strong quality culture enable AI solutions to deliver real, measurable impact for patients and clinicians.
- [Optimizing Imaging Outcomes: Why Lung Volume Control Can Make or Break the Success of a Respiratory Clinical Trial](https://thirona.eu/optimizing-imaging-outcomes-why-lung-volume-control-can-make-or-break-the-success-of-a-respiratory-clinical-trial/): By Thirona Editorial Team
- [10 years of innovating AI in lung imaging – What a journey!](https://thirona.eu/10-years-of-innovating-ai-in-lung-imaging-what-a-journey/): By dr. Eva van Rikxoort
- [Automatic airway analysis with artificial intelligence](https://thirona.eu/automatic-airway-analysis-with-artificial-intelligence/): By Rūdolfs Latišenko
- [Phenotyping vascular lung disease patients: new ways with imaging-based markers](https://thirona.eu/phenotyping-vascular-lung-disease-patients-new-ways-with-imaging-based-markers/): Featuring insights from prof. Julien Guiot, CHU Liege
- [From Scientist to CEO: My journey to pioneer AI in Precision Medicine](https://thirona.eu/from-scientist-to-ceo-my-journey-to-pioneer-ai-in-precision-medicine/): By Eva van Rikxoort, PhD
- [Thirona Spinout Thirona Retina BV Acquired by Revenio Group](https://thirona.eu/thirona-spinout-thirona-retina-bv-acquired-by-revenio-group/): Divestment of Thirona Retina BV to continue focus on pulmonary diseases and expanding within the interventional pulmonology space
- [Welcoming top clinical experts to Thirona’s Medical Advisory Board](https://thirona.eu/thirona-medical-advisory-board/): To achieve our mission of advancing personalized and tailored approaches to lung disease treatment and care, we are welcoming top clinical experts to Thirona's Medical Advisory Board.
- [Blackford and Thirona Partner to Enhance Lung Image Analysis](https://thirona.eu/blackford-and-thirona-partner-to-enhance-lung-image-analysis/): Blackford and Thirona announce a commercial partnership to bring the LungQ™ solution to healthcare professionals via the Blackford Platform.
- [Autonomous AI Revolutionizes Cancer Detection](https://thirona.eu/autonomous-ai-revolutionizes-cancer-detection/): The "Autonomous AI for Cancer Detection" project, a major collaboration between ScreenPoint Medical, Radboud University Medical Center (RUMC) and Thirona, is set to transform the landscape of cancer detection from 2025 to 2028. Supported by the European Fund for Regional Development (ERDF), the project aims to integrate autonomous AI into medical imaging to accelerate early cancer detection while reducing the intense workload on healthcare professionals.
- [Voiant and Thirona announce commercial partnership for full scope services in imaging-based clinical trials for pulmonary diseases.](https://thirona.eu/voiant-and-thirona-announce-commercial-partnership-for-full-scope-services-in-imaging-based-clinical-trials-for-pulmonary-diseases/): Voiant and Thirona have entered a global commercial partnership to provide full scope integral services for clinical trials (with AI-powered lung image analysis), building further on several years of a fruitful cooperation.
- [LungQ 3.0.0 receives FDA 510(k) clearance](https://thirona.eu/lungq-3-0-0-receives-fda-510k-clearance/): Thirona has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the latest update of its AI-based clinical software LungQ™ (v3.0.0)
- [Aidence, Incepto, and Thirona launch joint clinical solution to support the expansion of lung cancer screening in Europe  ](https://thirona.eu/aidence-incepto-thirona-lung-cancer-screening/): MedTech companies Aidence, Incepto, and Thirona jointly introduce a comprehensive AI-powered software package for lung cancer screening and the analysis of emphysema
- [Thirona Raises €7.5 Million New Financing](https://thirona.eu/new-investment-round-2023/): Thirona is thrilled to have secured €7,5 Million ($8 Million) of financing from HERAN Partners, Borski Fund and the EIC.
- [Pulmonary hypertension: ongoing research](https://thirona.eu/pulmonary-hypertension-ongoing-research/): 2 abstracts of major importance for advancing the treatment of pulmonary vascular diseases, and pulmonary hypertension in particular, were presented today at ATS 2023 International Conference in Washington by Julien Guiot from CHU de Liège.
- [Thirona awarded to receive EIC grant](https://thirona.eu/thirona-eic-grant/): Following the second 2023 EIC Accelerator cut-off in March, Thirona is awarded to receive European Innovation Council (EIC) funding.
- [Artificial Intelligence Could Enable Life-Saving Early Diagnosis and Advance the Treatment of Pulmonary Hypertension](https://thirona.eu/thirona-treatment-vascular-diseases/): Thirona’s AI-Based LungQ™AVX Reveals New Potential for Treatment of Vascular Diseases.
- [Thirona spins out the Retina business to pursue long-term growth plans](https://thirona.eu/thirona-spins-out-the-retina-business-to-pursue-long-term-growth-plans/): Following the growing market demand and recent expansion of RetCAD™, Thirona decided spins it out as per January 1st,
- [Bringing AI into hospitals – Empowering personalized patient treatment](https://thirona.eu/bringing-ai-into-hospitals/): Bringing AI into clinical care through integration partnerships with Philips & Incepto.
- [NLAIC Matchmaking for AI Startups in Healthcare](https://thirona.eu/nlaic-matchmaking-for-ai-startups-in-healthcare/): On November 24th the matchmaking in healthcare event took place, organized by the Netherlands AI coalition
- [Predictive powers of Thirona’s CAD4COVID in COVID-19 patients](https://thirona.eu/predictive-powers-cad4covid/): AI significantly increases efficiency in predicting the risk of deterioration of the COVID-19 patient’s condition.
- [ISO 27001 certification for Thirona assures that patients’ data is handled according to stringent information security guidelines](https://thirona.eu/iso-27001-certification-for-thirona-assures-that-patients-data-is-handled-according-to-stringent-information-security-guidelines/): Thirona is awarded ISO 27001 and NEN 7510 certifications.
- [Amazon Web Services supports Thirona’s innovation in diagnostic research](https://thirona.eu/amazon-web-services-supports-thironas-innovation-in-diagnostic-research/): Amazon Web Services grants Thirona AWS Promotional Credit under the DDI Program.
- [ATS 2022, San Fransisco: AI in medical imaging is taking off](https://thirona.eu/ats-2022/): American Thoracic Society 2022 was a great opportunity to meet the respiratory expert community
- [Thirona partners with Free Flow Medical for AI-powered clinical solutions to treat COPD patients](https://thirona.eu/thirona-partners-with-free-flow-medical-for-ai-powered-clinical-solutions-to-treat-copd-patients/): Thirona and Free Flow Medical signed a partnership agreement to provide clinicians with advanced high-precision tools for treatment planning.
- [Thirona and Pulmonx have extended their strategic partnership, which leverages Thirona’s AI-powered solutions in Pulmonx StratX® platform](https://thirona.eu/thirona-and-pulmonx-have-extended-their-strategic-partnership-which-leverages-thironas-ai-powered-solutions-in-pulmonx-stratx-platform/): Thirona BV and Pulmonx Corporation have extended their long-running strategic partnership.
- [Thirona appoints Chief Medical Officer](https://thirona.eu/thirona-appoints-chief-medical-officer/): We are very glad to announce that prof. Tiddens has joined Thirona.
- [Thirona closes financing round with HERAN Partners and Borski Fund](https://thirona.eu/thirona-closes-financing-round-with-heran-partners-and-borski-fund/): We are proud to inform that we have just closed a financing round with Belgian investment fund HERAN Partners and Borski Fund from the Netherlands.
- [Thirona is present at ATS and Radiology days](https://thirona.eu/thirona-is-present-at-ats-and-radiology-days/): Thirona is present during the congress of the American Thoracic Society from May 14-19.
- [Thirona’s artery-vein and segment segmentation helps in lung cancer surgeries](https://thirona.eu/thironas-artery-vein-and-segment-segmentation-helps-in-lung-cancer-surgeries/): Read the new paper on the added value of AI-based lung segmentation and VR technology in lung cancer surgery planning.
- [Thirona launches AI software for Cystic Fibrosis](https://thirona.eu/thirona-launches-ai-software-for-cystic-fibrosis/): Thirona developed an AI algorithm that revolutionizes cystic fibrosis (CF) care.
- [LUMC calculates lung damages COVID-19 patients with AI technology](https://thirona.eu/lumc-calculates-lung-damages-covid-19-patients-with-ai-technology/): Healthcare professionals at Leiden University Medical Centre can now use artificial intelligence to quickly and easily calculate whether a corona patient has suffered serious lung damage.
- [Update from Thirona](https://thirona.eu/update-from-thirona/): Due to COVID-19 further spread worldwide, we prepared an update on our work to better bridge the gap between medical image analysis and clinical use-ability.
- [The Canisius Wilhelmina Ziekenhuis in Nijmegen is now using CAD4COVID-CT in their clinical practice!](https://thirona.eu/the-canisius-wilhelmina-ziekenhuis-in-nijmegen-is-now-using-cad4covid-ct-in-their-clinical-practice/): Our CAD4COVID software will help to assess affected lung tissue in COVID-19 patients.
- [Thirona is now compliant with the new Medical Device Regulation](https://thirona.eu/thirona-is-now-compliant-with-the-new-medical-device-regulation/): We are especially proud to announce that Thirona successfully implemented the requirements and is now certified against the new MDR.
- [Thirona obtains patent for quantitative analysis of Cystic Fibrosis in children](https://thirona.eu/pragma/): The patent allows Thirona to develop an AI algorithm that will analyse CT scans to identify even the smallest abnormalities in the lungs, especially early on, ensuring that the right treatment can follow.
- [Thirona partners with P4O2 consortium to study long-term effects of COVID-19](https://thirona.eu/p4o2/): Public-private consortium P4O2 together with Thirona investigates risk factors for developing lung damage and chronic complaints after COVID-19 

## Pages
- [Other Diseases](https://thirona.eu/other-diseases/): In clinical studies, AI-based imaging assessment is increasingly used to support more objective evaluation of major lung disease areas such as COPD, cystic fibrosis, bronchiectasis, and severe asthma. At the same time, many other lung diseases present complex structural abnormalities that can benefit from more objective, quantitative assessment.
- [Mucus Plugs](https://thirona.eu/technology-lungq/mucus-plugs/): As a key feature of chronic respiratory disease, mucus plugging is increasingly recognized as a clinically relevant imaging metric and therapeutic target, with growing importance in both clinical research and the development of novel therapies. Thirona's AI-derived LungQ® Mucus Plug analysis (LungQ® MP) has been extensively validated across global research initiatives including COPDGene, EMBARC, and ENRICH and utilized to evaluate effectiveness of new therapies.
- [Therapeutic area – Bronchiectasis Disease](https://thirona.eu/therapeutic-areas/bronchiectasis-disease/): As a complex structural consequence of various underlying conditions, Bronchiectasis Disease is a clinically and radiologically heterogeneous disease. A deep understanding on disease mechanisms and optimized patient phenotyping will be essential for developing optimized patient treatment strategy.
- [Therapeutic area –  Severe Asthma](https://thirona.eu/therapeutic-areas/severe-asthma/): Severe asthma is characterized by airway inflammation, mucus plugs and structural abnormalities especially within small airways. While these changes have been identified in adult populations, the extent and prevalence have remained unknown in the pediatric population.
- [Therapeutic area – Cystic Fibrosis](https://thirona.eu/therapeutic-areas/cystic-fibrosis/): Cystic Fibrosis (CF) lung disease is defined by progressive structural airway abnormalities that begin in infancy. These changes often emerge before functional decline is detectable, persisting throughout a patient’s life despite therapeutic advances.
- [Coordinated Vulnerability Disclosure Policy](https://thirona.eu/coordinated-vulnerability-disclosure-policy/): Last updated: 17.12.2025
- [Therapeutic areas](https://thirona.eu/therapeutic-areas/)
- [Request an appointment](https://thirona.eu/events-contact-form/)
- [Webinar Access](https://thirona.eu/webinar-access/): Leave us your information in order to access our old webinars.
- [Search](https://thirona.eu/search/): Type a keyword above to search.
- [Lung Interventions](https://thirona.eu/pulmonary-interventions/): We partner with leading MedTech companies developing interventional devices, navigation technologies, and robotic bronchoscopy systems to advance the next generation of precision-driven pulmonary interventions.​
- [Therapeutic area – COPD](https://thirona.eu/therapeutic-areas/copd/): Despite progress in COPD care, effective assessment and treatment remain challenging. Spirometry provides functional insights but overlooks the structural complexity of the disease.
- [Privacy Policy](https://thirona.eu/privacy-policy/): Last updated: 19.02.2026
- [Evidence & Expertise – Insights](https://thirona.eu/evidence-expertise-insights/): Evidence & Expertise Insights Blogs More blogs Webinars more webinars Technology explainers More videos Publications highlights more publication highlights Talks & perspectives More Talks & Perspectives
- [Drug Development](https://thirona.eu/pharmaceutical-drug-development/): AI-powered quantitative chest CT analysis is increasingly vital in respiratory clinical trials, providing non-invasive, precise, and objective assessment of anatomical abnormalities and disease severity to complement traditional endpoints.
- [Technology](https://thirona.eu/technology-lungq/): LungQ® - our modular technology portfolio of advanced deep-learning algorithms for thoracic image analysis - offers market-unique segmentation and quantification capabilities for comprehensive assessment of lung anatomy and diseased lung regions.​
- [Sitemap](https://thirona.eu/sitemap/): Sitemap
- [Quality & Compliance](https://thirona.eu/quality-compliance/): At Thirona, quality, compliance and data protection are the foundation of how we design, validate and deliver our AI software solutions for lung image analysis. Meeting the highest international standards for safety, performance, and data protection, we ensure every measurement is reliable, every process traceable, and every patient’s data secure.
- [Blog](https://thirona.eu/blogs/)
- [News](https://thirona.eu/news/): Company news
- [Contacts](https://thirona.eu/about-us/contact/): info@thirona.eu
- [About us](https://thirona.eu/about-us/): https://thirona.eu/wp-content/uploads/2025/09/Thirona-10-Years-Eva-van-Rikxoort.mp4
- [Homepage](https://thirona.eu/): Building on our modular LungQ® technology, we translate advanced imaging intelligence into real-world impact, supporting our partners in developing novel therapies and advancing pulmonary interventions.

## Events
- [European Respiratory Society (ERS) Congress](https://thirona.eu/events/european-respiratory-society-ers-congress-2026/)
- [World Bronchiectasis Conference](https://thirona.eu/events/world-bronchiectasis-conference/)
- [Global Conference on Robotic Assisted Bronchoscopy RAB](https://thirona.eu/events/global-conference-on-robotic-assisted-bronchoscopy-rab/)
- [Spanish Society of Pulmonology and Thoracic Surgery (SEPAR) Congress](https://thirona.eu/events/spanish-society-of-pulmonology-and-thoracic-surgery-separ-congress/)
- [American Thoracic Society (ATS) International Conference](https://thirona.eu/events/american-thoracic-society-ats-international-conference/)
- [SEPAR 3rd RedCLIINIASMA Meeting](https://thirona.eu/events/separ-3rd-redcliiniasma-meeting/)
- [European Lung Cancer Congress](https://thirona.eu/events/european-lung-cancer-congress/)
- [European Congress of Radiology](https://thirona.eu/events/european-congress-of-radiology/)
- [International Forum on Respiratory Tract Infections](https://thirona.eu/events/international-forum-on-respiratory-tract-infections/)
- [Dutch Lung Congress 2026](https://thirona.eu/events/dutch-lung-congress-2026/)
- [Artificial Intelligence and Robotics for Lung Disease](https://thirona.eu/events/artificial-intelligence-and-robotics-for-lung-disease/)
- [International Workshop on Lung Health](https://thirona.eu/events/international-workshop-on-lung-health/)

## Videos
- [From invisible details to powerful insights – LungQ®](https://thirona.eu/technology-explainers/from-invisible-details-to-powerful-insights-lungq-2/)
- [From invisible details to powerful insights – LungQ® Mucus Plug Analysis](https://thirona.eu/technology-explainers/from-invisible-details-to-powerful-insights-lungq-mucus-plug-analysis/)
- [From invisible details to powerful insights – LungQ®](https://thirona.eu/technology-explainers/from-invisible-details-to-powerful-insights-lungq/)
- [LungQ™ AVX – deep characterization of the pulmonary vasculature](https://thirona.eu/technology-explainers/lungq-avx-deep-characterization-of-the-pulmonary-vasculature/)
- [LungQ™ – AI powered lung image analysis](https://thirona.eu/technology-explainers/lungq-ai-powered-lung-image-analysis/)
- [World Lung Day | Accelerating medical innovations for precision medicine in pulmonary diseases](https://thirona.eu/technology-explainers/world-lung-day-accelerating-medical-innovations-for-precision-medicine-in-pulmonary-diseases/)
- [LungQ™ identification of targeted treatment area for bronchoscopic interventions](https://thirona.eu/technology-explainers/lungq-identification-of-targeted-treatment-area-for-bronchoscopic-interventions/)
- [LungQ™ identification of targeted treatment area for preoperative planning](https://thirona.eu/technology-explainers/lungq-identification-of-targeted-treatment-area-for-preoperative-planning/)
- [LungQ™ identification of targeted treatment area for pulmonary segmentectomy](https://thirona.eu/technology-explainers/lungq-identification-of-targeted-treatment-area-for-pulmonary-segmentectomy/)
- [LungQ™ precise quantification of common and rare diseases](https://thirona.eu/technology-explainers/lungq-precise-quantification-of-common-and-rare-diseases/)

## Job Openings
- [Team Lead/Senior Software Engineer – C++](https://thirona.eu/career/team-lead-senior-software-engineer-c/): As a team lead and senior C++ software engineer at Thirona you will lead, and be part of, the team that develops and maintains the software framework and applications that execute the algorithms developed by our deep learning team. Applications include back-end routines for pre- and postprocessing for our image analysis models and executables to create visual reports for our clients.
- [Information Security Officer](https://thirona.eu/career/information-security-officer/): As Information Security Officer, you safeguard the security of medical/healthcare information across Thirona and coordinate our Information Security Management System (ISMS). You’ll define, maintain, and continually improve the ISMS, coordinate risk management, and communicate relevant information security matters throughout the organization. You will also serve as a point of contact for authorities and relevant industry groups, and ensure product safety, information security, and privacy risks are identified and addressed per our policies and procedures. You report to the Chief Operations Officer.
- [Data Engineer ](https://thirona.eu/career/data-engineer/): Our Development and Operations Team is committed to ensuring the continuous safety, security, and performance of all Thirona hardware and software systems. The team conducts daily system maintenance and guides the deployment of new systems to the organization within the framework of defined policies and code of Conduct. 

## Medical Advisers Board
- [Prof. Dr. Arnaud Bourdin, MD](https://thirona.eu/medical-advisory-board/prof-dr-arnaud-bourdin-md/): Prof. Bourdin is Head of Pulmonology and Professor of Respiratory Medicine at Hôpital Arnaud de Villeneuve, University of Montpellier, France, leading a research group focused on innovative treatments for asthma, COPD, IPF, and pulmonary hypertension. His scientific work explores COPD pathophysiology, severe asthma treatment, and iPSC biology, and he has served as Principal Investigator in major clinical trials, including COBRA and RAMSES.​
- [Prof. Dr. Patrick Flume, MD](https://thirona.eu/medical-advisory-board/prof-dr-patrick-flume-md/): Prof. Flume is a Distinguished Professor of Medicine and Pediatrics and Associate Vice President for Clinical Research at the Medical University of South Carolina. He serves as the Powers-Huggins Endowed Chair for Cystic Fibrosis (CF) and oversees a large CF center, as well as large clinical programs dedicated to patients with bronchiectasis and non-tuberculous mycobacterial (NTM) infections. He leads an intensive clinical research program for CF, bronchiectasis, and NTM, and is co-principal investigator for the South Carolina Clinical & Translational Research Institute.​
- [Dr. Eva Polverino, MD](https://thirona.eu/medical-advisory-board/dr-eva-polverino-md/): Dr. Polverino is Head of the Respiratory Infections Research Unit at Hospital Vall d’Hebron (VHIR, Barcelona), with research focused on bronchiectasis, cystic fibrosis, antimicrobial resistance, and respiratory infections in immunocompromised patients. She plays an active leadership role within the European Respiratory Society and is co-chair of the EMBARC registry, author of the first European Guidelines for Bronchiectasis, and principal investigator in numerous clinical trials.
- [Dr. Krish Bhadra, MD](https://thirona.eu/medical-advisory-board/dr-krish-bhadra-md/): Dr. Bhadra leads Interventional Pulmonology clinic at CHI Memorial Medical, focusing on minimally-invasive procedures for treatment of lung and airway conditions, including lung cancer and severe emphysema. His interests include research, diagnostic and therapeutic interventions for thoracic oncology patients and benign lung disease. As a leading bronchoscopist in the United States, he utilizes cutting-edge technology to navigate the intricacies of the airway and lungs. Dr. Bhadra was the first in the world to use digital tomosynthesis
- [Prof. Dr. Pallav Shah, MD](https://thirona.eu/medical-advisory-board/prof-dr-pallav-shah-md/): Dr. Shah is Professor of Respiratory Medicine at the National Heart & Lung Institute - Faculty of Medicine, and the lead clinician for lung cancer services at Royal Brompton Hospital and the Chelsea & Westminster Hospital. He is involved in the development of new bronchoscopic techniques for early detection and therapeutic interventions in lung cancer, using a combination of intra-operative imaging, novel devices and robotics to approach peripheral lung nodules. His current research interests also include the role of innovative treatments in COPD, from chronic bronchitis to emphysema, and airway diseases.
- [Prof. Dr. Dirk-Jan Slebos, MD](https://thirona.eu/medical-advisory-board/prof-dr-dirk-jan-slebos-md/): Prof. Slebos is Head of Pulmonary Medicine and Tuberculosis at University Medical Center Groningen and Professor of Interventional Pulmonology. Specialized in interventional bronchoscopy, he is one of the pioneers of the minimally invasive endobronchial treatment for COPD patients with severe emphysema. His areas of interest include severe COPD, lung failure, benign and malignant central airway pathology, innovative treatments for interventional bronchoscopy.

## Projects
- [AI-supported imaging insights platform for COPD care management](https://thirona.eu/projects/ai-supported-imaging-insights-platform-for-copd-care-management/)
- [Quantitative lung CT analysis helping to decode COPD pathology](https://thirona.eu/projects/quantitative-lung-ct-analysis-helping-to-decode-copd-pathology/)
- [3D visualization of thoracic surgery planning enabled by AI-driven anatomical segmentation ](https://thirona.eu/projects/3d-visualization-of-thoracic-surgery-planning-enabled-by-ai-driven-anatomical-segmentation/)
- [Clinical Expert Training Program on AI-Driven QCT in Severe Asthma Management](https://thirona.eu/projects/clinical-expert-training-program-on-ai-driven-qct-in-severe-asthma-management/)
- [QCT Analysis in Search of Predictive Biomarkers for Biologic Treatment in Severe Asthma ](https://thirona.eu/projects/ai-powered-quantitative-ct-analysis-in-search-of-predictive-biomarkers-for-biologic-treatment-in-severe-asthma/)
- [Collaborative European research in bronchiectasis ](https://thirona.eu/projects/collaborative-european-research-in-non-cystic-fibrosis-bronchiectasis/): Bronchiectasis has historically been a neglected "orphan" disease. The international EMBARC (The European Bronchiectasis Registry) network connects researchers worldwide to build capacity for multidisciplinary collaborative research. This collaboration enables researchers to answer fundamental questions across the spectrum of bronchiectasis including its epidemiology, etiology, microbiology, pathophysiology, clinical management, and prognosis 
- [Accelerating Early Lung Cancer Detection with Autonomous AI](https://thirona.eu/projects/autonomous-ai-for-cancer-detection/)
- [Evaluation of QCT metrics for COPD phenotyping in the COPDGene cohort](https://thirona.eu/projects/evaluation-of-qct-metrics-for-copd-disease-phenotyping-in-copdgene-cohort/): Building on over a decade of pioneering research from the COPDGene project, this ancillary study is designed to further advance the understanding of chronic obstructive pulmonary disease (COPD) through artificial intelligence–driven imaging biomarkers.
- [European initiative to standardize QCT metrics in CF population data](https://thirona.eu/projects/european-initiative-to-standardize-qct-outcomes-in-cf-population-data/): Thirona's solution quantifies structural lung abnormalities in the patient cohort, using its AI-based analyses . This approach automates the well-established PRAGMA-CF scoring method to provide detailed measurements from chest CT scans. Furthermore, it includes precise quantification of bronchial wall thickness, the bronchus-to-artery ratios (i.e., the LungQ® BA analysis), mucus plug volume and count (i.e., the LungQ® Mucus Plugging analysis), and air trapping (i.e., the LungQ® VERA analysis). This marks the first time the ECFS Patient Registry plans to integrate the AI-powered imaging outcome analysis into its database.
- [Global consortium for development of respiratory digital imaging biomarkers](https://thirona.eu/projects/osic/): Thirona made use of the data for research on automatized quantification and prognosis of IPF patients and a study on longitudinal changes in IPF patients. The OSIC database facilitates the search for digital imaging biomarkers, speeding up diagnosis and aiding in better understanding of individual prognosis and response to therapy.
- [Observational U.S. study investigating underlying genetic factors of COPD](https://thirona.eu/projects/copdgene/): Thirona is one of the research partners for the imaging arm of the study, providing AI-based quantitative CT scan analysis (emphysema quantification, airway measurements).

## Publications
- [Small Pulmonary Artery and Vein Volumes Independently Predict Oxygen Desaturation in Smokers](https://thirona.eu/publications/small-pulmonary-artery-and-vein-volumes-independently-predict-oxygen-desaturation-in-smokers/)
- [Correlation Between Segmental Bronchial Wall Thickness and Bronchoalveolar Lavage Markers of Inflammation and Mucus Before and After Elexacaftor-Tezacaftor-Ivacaftor Therapy](https://thirona.eu/publications/correlation-between-segmental-bronchial-wall-thickness-and-bronchoalveolar-lavage-markers-of-inflammation-and-mucus-before-and-after-elexacaftor-tezacaftor-ivacaftor-therapy/)
- [AI-Based Quantitative CT Can Characterize Structural Heterogeneity in Pi*ZZ Alpha-1 Antitrypsin Deficiency](https://thirona.eu/publications/ai-based-quantitative-ct-can-characterize-structural-heterogeneity-in-pizz-alpha-1-antitrypsin-deficiency/)
- [Concordance of Visual and Artificial Intelligence-Based Mucus Plug Detection on Computed Tomography in the COPDgene Study](https://thirona.eu/publications/concordance-of-visual-and-artificial-intelligence-based-mucus-plug-detection-on-computed-tomography-in-the-copdgene-study/)
- [AI-driven Quantitative CT Analysis of Structural Lung Changes After Benralizumab in Severe Asthma](https://thirona.eu/publications/ai-driven-quantitative-ct-analysis-of-structural-lung-changes-after-benralizumab-in-severe-asthma/)
- [Quantitative CT Analysis for Monitoring Mycobacteriophage Therapy in a Cystic-Fibrosis Patient With a Mycobacterium Abscessus Pulmonary Infection](https://thirona.eu/publications/quantitative-ct-analysis-for-monitoring-mycobacteriophage-therapy-in-a-cystic-fibrosis-patient-with-a-mycobacterium-abscessus-pulmonary-infection/)
- [Worsening lung function coupled with severe exacerbations is associated with increased rate of bronchial wall thickening](https://thirona.eu/publications/worsening-lung-function-coupled-with-severe-exacerbations-is-associated-with-increased-rate-of-bronchial-wall-thickening/)
- [Progression of structural lung disease and lung function in adolescents with cystic fibrosis](https://thirona.eu/publications/progression-of-structural-lung-disease-and-lung-function-in-adolescents-with-cystic-fibrosis/)
- [Development of quantitative CT image outcome for NTM lung disease interventions](https://thirona.eu/publications/development-of-quantitative-ct-image-outcome-for-ntm-lung-disease-interventions/)
- [The effects of metered cryospray on quantitative computed tomography metrics in patients with COPD with chronic bronchitis](https://thirona.eu/publications/the-effects-of-metered-cryospray-on-quantitative-computed-tomography-metrics-in-patients-with-copd-with-chronic-bronchitis/)
- [Successful endobronchial valve treatment in patients with an incomplete right upper lobe fissure](https://thirona.eu/publications/successful-endobronchial-valve-treatment-in-patients-with-an-incomplete-right-upper-lobe-fissure/)
- [Emphysema score difference can be used to determine small airways disease in severe COPD](https://thirona.eu/publications/emphysema-score-difference-can-be-used-to-determine-small-airways-disease-in-severe-copd/)
- [Artificial intelligence (AI)-based quantitative image analysis on vascular changes after lung transplantation: a pilot study](https://thirona.eu/publications/artificial-intelligence-ai-based-quantitative-image-analysis-on-vascular-changes-after-lung-transplantation-a-pilot-study/)
- [Structural lung abnormalities in children and  adults with cystic fibrosis after ETI using AI  automated algorithm](https://thirona.eu/publications/structural-lung-abnormalities-in-children-and-adults-with-cystic-fibrosis-after-eti-using-ai-automated-algorithm/)
- [AI-based mucus plug analysis to evaluate the effect of inhaled hypertonic saline in preschool children with CF: a randomized controlled trial](https://thirona.eu/publications/ai-based-mucus-plug-analysis-to-evaluate-the-effect-of-inhaled-hypertonic-saline-in-preschool-children-with-cf-a-randomized-controlled-trial/)
- [Investigating imaging markers in cystic fibrosis preschoolers using manual and automated algorithms](https://thirona.eu/publications/investigating-imaging-markers-in-cystic-fibrosis-preschoolers-using-manual-and-automated-algorithms/)
- [The Effects of Corrective Surgery on Lung  Structure Assessed with Chest CT in Adolescents  with Idiopathic Scoliosis](https://thirona.eu/publications/the-effects-of-corrective-surgery-on-lung-structure-assessed-with-chest-ct-in-adolescents-with-idiopathic-scoliosis/)
- [Automatic detection of mucus plugs on computed tomography scans in severe paediatric asthma](https://thirona.eu/publications/automatic-detection-of-mucus-plugs-on-computed-tomography-scans-in-severe-paediatric-asthma/)
- [Automated analysis of airway remodeling and emphysema across GOLD Stages: Insights in COPD Severity](https://thirona.eu/publications/automated-analysis-of-airway-remodeling-and-emphysema-across-gold-stages-insights-in-copd-severity/)
- [AI-measured bronchial dimensions and emphysema: A duo for predicting airflow limitation in COPD](https://thirona.eu/publications/ai-measured-bronchial-dimensions-and-emphysema-a-duo-for-predicting-airflow-limitation-in-copd/)
- [The effect of Elexacaftor/Tezacaftor/Ivacaftor (ETI) on bronchial tapering as marker of bronchial dilatation in people with CF aged 12 above (RECOVER study)](https://thirona.eu/publications/the-effect-of-elexacaftor-tezacaftor-ivacaftor-eti-on-bronchial-tapering-as-marker-of-bronchial-dilatation-in-people-with-cf-aged-12-above-recover-study/)
- [Automatic bronchus artery and mucus plug  analysis of adult bronchiectasis disease patients treated with dornase alfa](https://thirona.eu/publications/automatic-bronchus-artery-and-mucus-plug-analysis-of-adult-bronchiectasis-disease-patients-treated-with-dornase-alfa/)
- [Endobronchial valve treatment improves chest-CT diaphragm configuration in COPD](https://thirona.eu/publications/endobronchial-valve-treatment-improves-chest-ct-diaphragm-configuration-in-copd/)
- [Quality of CT based airway segmentation software for navigation bronchoscopy](https://thirona.eu/publications/quality-of-ct-based-airway-segmentation-software-for-navigation-bronchoscopy/)
- [Automated measures of bronchial outer diameter tapering across different COPDGene GOLD classes](https://thirona.eu/publications/automated-measures-of-bronchial-outer-diameter-tapering-across-different-copdgene-gold-classes/)
- [COPD progressors vs. non-progressors: 10-year change in Bronchus-Artery ratios & mucus plugs](https://thirona.eu/publications/copd-progressors-vs-non-progressors-10-year-change-in-bronchus-artery-ratios-mucus-plugs/)
- [Lobar differences on chest CTs of bronchiectasis patients from the EMBARC registry](https://thirona.eu/publications/lobar-differences-on-chest-cts-of-bronchiectasis-patients-from-the-embarc-registry/)
- [Fibrotic and vascular abnormalities quantified by an AI-based model are associated with outcomes in patients with idiopathic pulmonary fibrosis](https://thirona.eu/publications/fibrotic-and-vascular-abnormalities-quantified-by-an-ai-based-model-are-associated-with-outcomes-in-patients-with-idiopathic-pulmonary-fibrosis/)
- [Effect of elexacaftor–tezacaftor–ivacaftor on bronchial dilatations in adolescents with cystic fibrosis: a multicentre prospective observational study](https://thirona.eu/publications/effect-of-elexacaftor-tezacaftor-ivacaftor-on-bronchial-dilatations-in-adolescents-with-cystic-fibrosis-a-multicentre-prospective-observational-study/)
- [The impact of dornase alfa on imaging features of bronchiectasis](https://thirona.eu/publications/the-impact-of-dornase-alfa-on-imaging-features-of-bronchiectasis/)
- [Finding the optimal regimen for Mycobacteroides abscessus treatment  (FORMaT) in people with Mycobacteroides abscessus pulmonary disease: a multicentre, randomised, multi-arm, adaptive platform trial](https://thirona.eu/publications/finding-the-optimal-regimen-for-mycobacteroides-abscessus-treatment-format-in-people-with-mycobacteroides-abscessus-pulmonary-disease-a-multicentre-randomised-multi-arm-adaptive-platform-trial/)
- [Automated computed tomographic analysis of bronchial thickness and mucus plugs in bronchiectasis with asthma](https://thirona.eu/publications/automated-computed-tomographic-analysis-of-bronchial-thickness-and-mucus-plugs-in-bronchiectasis-with-asthma/)
- [Pseudomonas infections persisting after CFTR modulators are widespread throughout the lungs and drive lung inflammation](https://thirona.eu/publications/pseudomonas-infections-persisting-after-cftr-modulators-are-widespread-throughout-the-lungs-and-drive-lung-inflammation/)
- [Effect of High Altitude on Small Pulmonary Vein and Artery Volume in the COPDGene Cohort: Towards Better Understanding of Lung Physiology and Pulmonary Disease](https://thirona.eu/publications/effect-of-high-altitude-on-small-pulmonary-vein-and-artery-volume-in-the-copdgene-cohort-towards-better-understanding-of-lung-physiology-and-pulmonary-disease/)
- [Validation of an artificial intelligence-based automated PRAGMA and  mucus plugging algorithm in pediatric cystic fibrosis](https://thirona.eu/publications/elexacaftor-tezacafor-ivacaftor-improves-bronchial-dilatation-in-a-real-world-cohort-of-adolescents-with-cystic-fibrosis-2/)
- [Elexacaftor/tezacafor/ivacaftor improves bronchial dilatation in a real-world cohort of adolescents with cystic fibrosis](https://thirona.eu/publications/elexacaftor-tezacafor-ivacaftor-improves-bronchial-dilatation-in-a-real-world-cohort-of-adolescents-with-cystic-fibrosis/)
- [Measuring segmental lung changes of Cystic Fibrosis patients before and after Elexacaftor-Tezacaftor-Ivacaftor (ETI) with an automated analysis method](https://thirona.eu/publications/improvements-in-structural-lung-disease-in-people-with-cf-aged-12-and-above-on-elexacaftor-tezacaftor-ivacaftor-eti-are-sustained-for-up-to-two-years-2/)
- [Improvements in structural lung disease in people with CF aged 12 and above on Elexacaftor/Tezacaftor/Ivacaftor (ETI) are sustained for up to two years](https://thirona.eu/publications/improvements-in-structural-lung-disease-in-people-with-cf-aged-12-and-above-on-elexacaftor-tezacaftor-ivacaftor-eti-are-sustained-for-up-to-two-years/)
- [Airway mucus plugging in chronic bronchitis and the impact of Bronchial Rheoplasty](https://thirona.eu/publications/airway-mucus-plugging-in-chronic-bronchitis-and-the-impact-of-bronchial-rheoplasty/)
- [Association of Pulmonary Vascular Metrics on CT With Hemodynamic Alterations in Pulmonary Hypertension](https://thirona.eu/publications/association-of-pulmonary-vascular-metrics-on-ct-with-hemodynamic-alterations-in-pulmonary-hypertension/)
- [Changes in Low Attenuation Regions and Arterial and Venous Blood Volume Distribution in Response to CFTR Modulator Therapy in People With Cystic Fibrosis](https://thirona.eu/publications/changes-in-low-attenuation-regions-and-arterial-and-venous-blood-volume-distribution-in-response-to-cftr-modulator-therapy-in-people-with-cystic-fibrosis/)
- [Elexacaftor-Tezacaftor-Ivacaftor Reduces Bronchial Widening and Thickening in Adolescents With Cystic Fibrosis](https://thirona.eu/publications/elexacaftor-tezacaftor-ivacaftor-reduces-bronchial-widening-and-thickening-in-adolescents-with-cystic-fibrosis/)
- [Assessment of 10-year Progression in COPDGene Using Automated Measurements of Bronchus-Artery Ratios and Mucus Plugging](https://thirona.eu/publications/assessment-of-10-year-progression-in-copdgene-using-automated-measurements-of-bronchus-artery-ratios-and-mucus-plugging/)
- [Introduction of Ivacaftor/Lumacaftor in Children With Cystic Fibrosis Homozygous for F508del in the Netherlands: A Nationwide Real-Life Study](https://thirona.eu/publications/introduction-of-ivacaftor-lumacaftor-in-children-with-cystic-fibrosis-homozygous-for-f508del-in-the-netherlands-a-nationwide-real-life-study/)
- [Automated method of bronchus and artery dimension measurement in an adult bronchiectasis population](https://thirona.eu/publications/automated-method-of-bronchus-and-artery-dimension-measurement-in-an-adult-bronchiectasis-population/)
- [Effect of Lung Volume on Airway and Artery Analysis on Chest Computed Tomography in Chronic Obstructive Pulmonary Disease](https://thirona.eu/publications/effect-of-lung-volume-on-airway-and-artery-analysis-on-chest-computed-tomography-in-chronic-obstructive-pulmonary-disease/)
- [Higher pulmonary artery and vein volumes are associated with disease severity and mortality in smokers with and without COPD](https://thirona.eu/publications/higher-pulmonary-artery-and-vein-volumes-are-associated-with-disease-severity-and-mortality-in-smokers-with-and-without-copd/)
- [Airway Thickening, Mucus Plugs and Eosinophilia in Bronchiectasis and Asthma](https://thirona.eu/publications/airway-thickening-mucus-plugs-and-eosinophilia-in-bronchiectasis-and-asthma/)
- [Automatic analysis of bronchus-artery ratios and mucus plugs of 640 chest CTs of EMBARC bronchiectasis patients](https://thirona.eu/publications/automatic-analysis-of-bronchus-artery-ratios-and-mucus-plugs-of-640-chest-cts-of-embarc-bronchiectasis-patients/)
- [Automatic mucus plugging analysis on chest computed tomography in children with primary ciliary dyskinesia](https://thirona.eu/publications/automatic-mucus-plugging-analysis-on-chest-computed-tomography-in-children-with-primary-ciliary-dyskinesia/)

## Talks & Perspectives
- [Talk & Perspective 2](https://thirona.eu/talk-and-perspective/talk-perspective-2/): Talk & Perspective 2 text
- [Talk & Perspective1](https://thirona.eu/talk-and-perspective/talk-perspective1/): Talk & Perspective1 text

## Webinars
- [Comprehensive mucus analysis for mucus-obstructive disease with AI](https://thirona.eu/webinars/comprehensive-mucus-analysis-for-mucus-obstructive-disease-with-ai/)
- [AI meets chest imaging: A new era of precision](https://thirona.eu/webinars/ai-meets-chest-imaging-a-new-era-of-precision/)
- [Advancing Bronchiectasis Clinical Trials with AI-Powered Image Analysis ](https://thirona.eu/webinars/ai-powered-ct-imaging-for-smarter-clinical-trials-in-bronchiectasis-treatment/)

## Categories
- [Blog](https://thirona.eu/category/blog/)
- [Interviews](https://thirona.eu/category/interview/)
- [News](https://thirona.eu/category/news/)
- [Press Releases](https://thirona.eu/category/press-release/)
- [Product News](https://thirona.eu/category/product-news/)
- [Technology Explainer](https://thirona.eu/category/technology-explainer/)
- [Uncategorised](https://thirona.eu/category/uncategorised/)

## Anatomies
- [Bronchi](https://thirona.eu/anatomy/bronchus/)
- [Parenchyma](https://thirona.eu/anatomy/parenchyma/)
- [Vasculature](https://thirona.eu/anatomy/vascular/)

## Measurements
- [Airway Analysis](https://thirona.eu/measurement/airway-analysis/)
- [AVX](https://thirona.eu/measurement/avx/)
- [BA](https://thirona.eu/measurement/ba/)
- [Fissure Completeness](https://thirona.eu/measurement/fissure-completeness/)
- [Lung Volume](https://thirona.eu/measurement/lung-volume/)
- [MP](https://thirona.eu/measurement/mp/)
- [Navia](https://thirona.eu/measurement/navia/)
- [PRAGMA AI](https://thirona.eu/measurement/pragma-ai/)
- [PXT](https://thirona.eu/measurement/pxt/)
- [VERA](https://thirona.eu/measurement/vera/)

## Publication types
- [Exploratory](https://thirona.eu/publication-type/exploratory/)
- [Other](https://thirona.eu/publication-type/other/)
- [Performance validation](https://thirona.eu/publication-type/performance-validation/)
- [Treatment efficacy](https://thirona.eu/publication-type/treatment-efficacy/)

## Therapeutical Areas
- [Adolescent Idiopathic Scoliosis (AIS)](https://thirona.eu/therapeutical-area/adolescent-idiopathic-scoliosis-ais/)
- [Alpha-1 Antitrypsin Deficiency](https://thirona.eu/therapeutical-area/alpha-1-antitrypsin-deficiency/)
- [Bronchiectasis disease](https://thirona.eu/therapeutical-area/bronchiectasis-disease/)
- [Bronchoscopic Interventions](https://thirona.eu/therapeutical-area/bronchoscopic-interventions/)
- [COPD](https://thirona.eu/therapeutical-area/copd/)
- [COPD-chronic airway disease](https://thirona.eu/therapeutical-area/copd-chronic-airway-disease/)
- [Cystic Fibrosis](https://thirona.eu/therapeutical-area/cystic-fibrosis/)
- [Interstitial Lung Disease](https://thirona.eu/therapeutical-area/interstitial-lung-disease/)
- [Lung Surgery](https://thirona.eu/therapeutical-area/lung-surgery/)
- [Lung transplantation](https://thirona.eu/therapeutical-area/lung-transplantation/)
- [Nontuberculous mycobacteria (NTM) lung disease](https://thirona.eu/therapeutical-area/nontuberculous-mycobacteria-ntm-lung-disease/)
- [Primary Ciliary Dyskinesia](https://thirona.eu/therapeutical-area/primary-ciliary-dyskinesia/)
- [Pulmonary Hypertension](https://thirona.eu/therapeutical-area/pulmonary-hypertension/)
- [Severe Asthma](https://thirona.eu/therapeutical-area/asthma/)